LEVOFLOXACIN | A200839 | MACLEODS PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al 4 patentsANDA 200839pimobendan | D.N.J. | 2026-03-18 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.2811
per ea
Lowest NADAC/Unit
$0.1115
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 33342053332LEVOFLOXACIN 750 MG TABLET | $0.2811 | EA | Generic | — | 2026-06-17 |
| 33342053208LEVOFLOXACIN 500 MG TABLET | $0.1398 | EA | Generic | — | 2026-06-17 |
| 33342053108LEVOFLOXACIN 250 MG TABLET | $0.1115 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.